SIGA
- SIGA Technologies, Inc.
()
Overview
Company Summary
SIGA Technologies, Inc. is a biotechnology company that focuses on the development of countermeasures against infectious diseases. The company primarily specializes in the research and development of antiviral drugs to combat some of the most dangerous and potentially lethal pathogens.
SIGA's main area of expertise lies in smallpox antiviral treatments. Smallpox is a highly contagious and historically devastating disease caused by the variola virus. While smallpox no longer exists naturally in the world, it is considered a potential bioterrorism threat due to stored virus samples. SIGA has dedicated significant resources to develop an antiviral drug called TPOXX (tecovirimat) to combat the effects of smallpox infection.
TPOXX is an oral antiviral medication designed to treat and prevent complications arising from smallpox infection. It is known to be effective against various strains of the virus, including those that may be resistant to other treatments. The drug works by inhibiting the replication of the virus, limiting its ability to spread and causing harm to the infected individual.
Besides their focus on smallpox, SIGA Technologies is also engaged in the research and development of antiviral therapies for other contagious diseases. Their goal is to create innovative treatment options to safeguard public health and minimize the impact of infectious diseases.